Literature DB >> 33527451

Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.

Kebede H Begna1, Naseema Gangat1, Aref Al-Kali1, Mark R Litzow1, William J Hogan1, Mrinal M Patnaik1, Animesh Pardanani1, C Christopher Hook1, Alexandra P Wolanskyj1, Michelle A Elliott1, Curtis A Hanson2, Rhett P Ketterling3, Ayalew Tefferi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33527451     DOI: 10.1002/ajh.26112

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

Authors:  Christoph Röllig; Pierre-Yves Dumas; Pau Montesinos; Christian Récher; Emilie Bérard; Sarah Bertoli; Arnaud Pigneux; Suzanne Tavitian; Michael Kramer; Hubert Serve; Martin Bornhäuser; Uwe Platzbecker; Carsten Müller-Tidow; Claudia D Baldus; David Martínez-Cuadrón; Josefina Serrano; Pilar Martínez-Sánchez; Eduardo Rodríguez Arbolí; Cristina Gil; Juan Bergua; Teresa Bernal; Adolfo de la Fuente Burguera; Eric Delabesse; Audrey Bidet
Journal:  Blood Cancer J       Date:  2022-07-11       Impact factor: 9.812

2.  Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.

Authors:  Evan M Cherry; Diana Abbott; Maria Amaya; Christine McMahon; Marc Schwartz; Julie Rosser; Audrey Sato; Jeffrey Schowinsky; Anagha Inguva; Mohd Minhajuddin; Shanshan Pei; Brett Stevens; Amanda Winters; Craig T Jordan; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2021-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.